Our pipeline includes a clinical-stage therapeutic candidate for the treatment of chronic HBV and development candidates for the treatment of high-recurrence genital herpes and chronic HDV. Our research programs focus on the discovery of additional novel antiviral mechanisms for serious viral diseases.
Long Acting HPIs
High-recurrence genital herpes
Hepatitis B & D
|HPI: Helicase-primase inhibitor; NNPI: Non-nucleoside polymerase inhibitor; CAM: Capsid assembly modulator; IFNAR: Interferon-α receptor
A pipeline strategy designed to target serious viral diseases
In our relentless pursuit to discover novel antivirals to treat serious viral diseases and to bring finite and curative treatments to HBV patients, our pipeline is focused on the following areas:
- Long-acting helicase inhibitors for high-recurrence genital herpes caused by herpes simplex virus type 2 (HSV-2)
- Pan-herpes polymerase inhibitors (NNPI) for transplant-associated infections
- Novel, bioavailable small molecule inhibitors of HBV and HDV viral entry that potently block infection of hepatocytes for both viruses
- Novel, bioavailable, liver-focused small molecule agonists of the interferon pathway that are able to activate antiviral cellular responses as well as engage the innate and adaptive immune systems
- Potent, next generation capsid assembly modulator designed to maximally block the formation of new cccDNA
Programs advancing new small molecule compounds with novel targets and mechanisms
Our research team is focused on proprietary research to discover and develop novel antivirals to treat serious viral diseases. We are advancing two herpesvirus development candidates, ABI-5366 and ABI-1179, long-acting helicase-primase inhibitors of HSV-2 for patients with high-recurrence genital herpes, and are also progressing a research program for a pan-herpes NNPI for transplant-associated viral infections.
In HBV/HDV, we have a clinical stage potent, next generation CAM candidate, ABI-4334 (4334), optimized for significantly increased potency against cccDNA formation and new virus production versus first-generation CAMs. 4334 has completed a Phase 1a clinical study. We are also advancing a development candidate, ABI-6250, employing a small molecule approach to inhibit viral entry for HBV and hepatitis delta virus (HDV), which is estimated to impact approximately 4.5 percent of those chronically infected with HBV – approximately 12 million people globally. Our portfolio also includes a novel orally-bioavailable interferon-α receptor (IFNAR) agonist program that is designed to selectively activate the interferon-α pathway in the liver while reducing systemic exposure to improve tolerability.
More information about our clinical trials can be found at www.clinicaltrials.gov.